2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.04 Al-Obeidi

PP01.04 Al-Obeidi - Poster

Pdf Summary

The document discusses a study on the impact of ARID1A mutations on the efficacy of immune checkpoint inhibitor (ICI) therapy in patients with stage IV non-small cell lung cancer (NSCLC). The study analyzed data from 85 patients with ARID1A mutations and 254 control patients without the mutations. Results showed that ARID1A mutations were associated with higher PD-L1 expression and tumor mutational burden. Patients with ARID1A mutations who received ICI had a significant improvement in progression-free survival (PFS), though this difference was lost when oncogene-driven NSCLC patients were excluded from the analysis. The study emphasizes the need for larger prospective studies to explore ARID1A as a composite biomarker in combination with other predictors for treatment outcomes. The document provides detailed molecular features, treatment history, and efficacy outcomes among patients with ARID1A mutations. The study, conducted across multiple cancer centers between 2013 and 2020, aims to contribute to the understanding of ARID1A mutations in NSCLC and their impact on ICI therapy. Further research is recommended to explore the potential of ARID1A mutations as a predictive marker in combination with other factors for personalized treatment approaches in NSCLC.

Keywords

ARID1A mutations

immune checkpoint inhibitor therapy

non-small cell lung cancer

PD-L1 expression

tumor mutational burden

progression-free survival

oncogene-driven NSCLC

composite biomarker

treatment outcomes

personalized treatment approaches